VTGN (Vistagen Therapeutics) Float Percentage Of Total Shares Outstanding: 99.81% (As of Jun. 29, 2026)


VTGN Vistagen Therapeutics Inc VTGN
40 GF Score
Price $0.76
GF Value $2.20
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Float Percentage Of Total Shares Outstanding?

Vistagen Therapeutics VTGN +8.26% 40 Float Percentage Of Total Shares Outstanding is 99.81% as of Jun. 29, 2026. GuruFocus rates VTGN with a GF Score™ of 40/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Vistagen Therapeutics's float shares is 40.95 Mil. Vistagen Therapeutics's total shares outstanding is 41.03 Mil. Vistagen Therapeutics's float percentage of total shares outstanding is 99.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Vistagen Therapeutics's Insider Ownership is 1.23%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Vistagen Therapeutics's Institutional Ownership is 43.35%.

VTGN
40GF Score
Vistagen Therapeutics Inc VTGN
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistagen Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Vistagen Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=40.95/41.03
=99.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 99.81% mean?
Vistagen Therapeutics (VTGN) has a Float Percentage Of Total Shares Outstanding of 99.81% as of Jun. 29, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Vistagen Therapeutics and its competitors.
Is Vistagen Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Vistagen Therapeutics' current Float Percentage Of Total Shares Outstanding is 99.81%. Overall, Vistagen Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Float Percentage Of Total Shares Outstanding compare to PSTV and KYNB?
Vistagen Therapeutics' Float Percentage Of Total Shares Outstanding of 99.81% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Vistagen Therapeutics and its competitors. Vistagen Therapeutics's current Float Percentage Of Total Shares Outstanding is 99.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vistagen Therapeutics (VTGN) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.76 — trading 65.3% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 99.81%. Vistagen Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Vistagen Therapeutics (VTGN), the current Float Percentage Of Total Shares Outstanding is 99.81% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistagen Therapeutics (VTGN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued. The current stock price of $0.76 is trading 65.3% below its estimated GF Value™ of $2.20. GuruFocus considers Vistagen Therapeutics to be Possible Value Trap.

Key valuation signals for VTGN:

  • Float Percentage Of Total Shares Outstanding: 99.81%
  • GF Value™: $2.20 vs. price of $0.76 (65.3% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistagen Therapeutics Business Description

Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
40GF Score

Get the complete analysis for VTGN

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price
$2.20
GF Value